您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Acamprosate calcium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Acamprosate calcium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Acamprosate calcium图片
CAS NO:77337-73-6
包装与价格:
包装价格(元)
10mM (in 1mL Water)电议
50mg电议

产品介绍
阿坎酸钙 (Campral EC) 是一种 GABA 受体激动剂和谷氨酸能系统调节剂;减少酒精成瘾动物模型中的酒精消耗。
Cas No.77337-73-6
别名阿坎酸钙,Calcium N-acetylhomotaurinate; Campral EC
化学名calcium;3-acetamidopropane-1-sulfonate
Canonical SMILESCC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
分子式C10H20CaN2O8S2
分子量400.48
溶解度≥ 40 mg/mL in Water
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.IC50 value:Target: GABA receptorAcamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol.

References:
[1]. Preuss UW. Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.).Alcohol Clin Exp Res. 2012 Jun;36(6):967-9. doi: 10.1111/j.1530-0277.2012.01827.x.
[2]. Witkiewitz K, Saville K, Hamreus K.Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility.Ther Clin Risk Manag. 2012;8:45-53.
[3]. Gahr M, et al. Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy.Nervenarzt. 2012 Aug 15.
[4]. Palucha-Poniewiera A, Pilc A.Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6.
[5]. Hinton DJ, et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1.Neuropharmacology. 2012 Jun;62(8):2480-8.